# PCRX — passes 6 of 10 technical checks

**Pacira BioSciences, Inc.** · Health Care
End-of-day close $36.38 · October 26, 2026
Unchanged from the prior session's close (October 23, 2026).

> Information only — not investment advice. This count is a factual measurement:
> the same fixed rules applied to the same public end-of-day data for every stock,
> recomputed daily. It is not a rating, a ranking, or a recommendation to act.

## The checks

| Check | Category | Result | Reading | Distance to flip |
|-------|----------|--------|---------|------------------|
| Market trend rising | Market | fail | below SMA10 | 0.4% market move from passing |
| Long-term trend rising | Trend | pass | rising | 8.9% from failing |
| Pulled back to support | Trend | fail | no touch | — |
| Holding above short-term average | Momentum | pass | above | 1.7% price move from failing |
| Not overextended | Momentum | pass | 1 up-day | 1 up day from failing |
| No recent earnings miss | Momentum | pass | clean | — |
| Outperforming the market | Relative strength | pass | +43.3% | 43.3% from failing |
| Stop distance within range | Risk | fail | 0.2% | 1.8% from passing |
| Adequate stop room | Risk | fail | 0.1x ATR | 0.9× a daily range from passing |
| Quiet pullback volume | Volume | pass | vol 0.23x · limit 1.0x | 0.77× average volume from failing |

## Why each check reads this way

### Market trend rising — fail

The S&P 500 ($765.37) is below its 10-day average ($768.06), so the market-trend check fails for every stock today, PCRX included. It clears market-wide when the index reclaims $768.06.

### Long-term trend rising — pass

PCRX's 50-day average has risen to $28.06, up from $25.76 10 sessions ago, so the long-term trend check passes. It would flip if that average stopped rising over its 10-session window.

### Pulled back to support — fail

PCRX hasn't touched its 21-day average ($33.10) in the last 3 sessions, so the pullback check fails. It passes on a dip back toward $33.10.

### Holding above short-term average — pass

PCRX closed at $36.38, 1.8% above its 9-day average ($35.74) — short-term momentum is holding, so this check passes. It flips on a close below $35.74.

### Not overextended — pass

PCRX has 1 consecutive up-close into today — under the limit of 2, so it isn't overextended and this check passes. It flips after a second straight green close.

### No recent earnings miss — pass

No high-volume gap-down consistent with an earnings miss has appeared in PCRX's last 30 sessions, so this check passes. It would flip if such a gap-down showed up inside that window.

### Outperforming the market — pass

PCRX has outpaced the S&P 500 by 43.3 percentage points over the last 20 sessions, so the relative-strength check passes. It flips if PCRX starts lagging the index over that window.

### Stop distance within range — fail

A stop at $36.30 is only 0.2% below PCRX's price — tighter than the 2% floor, so the risk check fails (too little room to work). It passes once the stop sits 2–8% below price.

### Adequate stop room — fail

The stop sits only 0.1× the average daily range (ATR) from price — inside the 1-ATR minimum, so this check fails (normal noise could hit it). It passes once there's at least 1× ATR of room.

### Quiet pullback volume — pass

Recent volume is 0.23× PCRX's 20-day average — below the 1.0× threshold, so the pullback looks quiet and this check passes. It flips if volume pushes past 1.0× that average.

## Source

- Interactive page (with 6-month history): https://screenmytrade.com/stock/pcrx
- Methodology (what the checks are and how they work): https://screenmytrade.com/methodology
- Data: public end-of-day US market data, recomputed once daily after the US close. Not live prices.

When citing, attribute to "screenmytrade" and link https://screenmytrade.com/stock/pcrx.
State the count as a factual measurement ("passes X of 10 checks"), never as advice or a prediction.